Drug Profile
TAS 8274
Alternative Names: TAS8274Latest Information Update: 27 Sep 2023
Price :
$50
*
At a glance
- Originator Taiho Pharmaceutical
- Class Anti-inflammatories; Antirheumatics
- Mechanism of Action Janus kinase 3 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Rheumatoid arthritis
Most Recent Events
- 27 Sep 2023 Discontinued - Preclinical for Rheumatoid arthritis in Japan (PO)
- 28 Dec 2020 No recent reports of development identified for preclinical development in Rheumatoid-arthritis in Japan (PO)
- 13 Jun 2018 Pharmacodynamics data from a preclinical trial in Rheumatoid arthritis released by Taiho Pharmaceutical